In a surprise move Tuesday, the FDA rejected Orexigen’s proposed new diet drug Contrave, saying the company needed to run another study of its cardiovascular risks. With this rejection, all three of a slate of similar diet drug…
Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting — if not always positive — year. Here’s our rundown of the…
After the U.S. Food and Drug Administration rejected two other weight-loss pills earlier this year, an advisory panel has recommended the approval of Orexigen Therapeutics’s Contrave. If the FDA follows the recommendation, Cont…
Vivus shares are soaring this morning, even though the U.S. Food and Drug Administration rejected the drugmaker’s obesity drug Qnexa yesterday. Investors are hoping that the FDA’s rejection, which includes a request for more sa…
Arena Pharmaceuticals announced, as expected, the U.S. Food and Drug Administration did not approve its weight loss drug Lorcaserin for patients who are obese and overweight because the potential risks outweigh the minimal effi…